Posters

Lens exchange for toric customized FIL611T (Soleko) IOL in the eyes with induced astigmatism after previously performed corneal surgery and in eyes with high irregular astigmatism

Poster Details

First Author: D. Dementiev RUSSIAN FEDERATION

Co Author(s):    M. Sysoeva   A. Shipunova                 

Abstract Details

Purpose:

To evaluate visual outcomes, refractive result, stability and efficacy after toric FIL611T IOL (Soleko, Italy) implantation in the eyes with induced astigmatism after previously performed corneal operations and in the eyes with high irregular astigmatism

Setting:

International Center for Ophthalmology, Moscow, RussiaBlue Eye, Centro di Microchirurgia Oculare, and Centro Oculistico Capitanio, Milano, Italy

Methods:

We reviewed 6 eyes of 5 patients undergone lens exchange for customized toric IOL (Soleko.Italy ) implantation.Average age 51 y.o. 3 eyes of 3 patients after previously performed keratoplasty PKP in keratoconus and Radial Keratotomy RK); 2 eyes of one patient in intact eyes with high myopia and stable keratoconus.Astigmatism ranged from -1.55 to -7.33 D and spherical equivalent SE ranged from -7.6±7.6 D to -0.4±1.0.The mean follow-up period was about 6.0 months.Autorefractometry,corneal topography,wave front abberometry,uncorrected distance visual acuity (UCVA), corrected distance visual acuity (CDVA), optical biometry,intraocular pressure (IOP), OCT Visante, OCT Cirrus,endothelial cell (EC) loss were measured

Results:

The mean SE changed from -7.6±7.6 D to -0.4±1.0, cylinder changed from -5.2±1.5 D to -0.6±0.8 D. The UCVA improved from 1.0±0.5 (logMAR) to 0.1 ±0.1 The CDVA changed from 0.2±0.1 (logMAR) to 0.1 ±0.1 .The lens position at 0-180 degree was stable. No statistically EC induced by the lens exchange. No induced glaucoma or inflammation was observed.

Conclusions:

The customized FIL611T IOL (Soleko, Italy) implantation shows good visual outcomes, efficacy and stability of results in cases of induced astigmatism after previously performed corneal operations and in the eyes with high irregular astigmatism

Financial Disclosure:

NONE